Systemic IFN-β gene therapy results in long-term survival in mice with established colorectal liver metastases |
| |
Authors: | Hiroomi Tada David J Maron Eugene A Choi James Barsoum Hanqin Lei Qing Xie Wenbiao Liu Lee Ellis A David Moscioni John Tazelaar Stephen Fawell Xiao Qin Kathleen J Propert Alan Davis Douglas L Fraker James M Wilson and Francis R Spitz |
| |
Institution: | Department of Surgery, Division of Surgical Oncology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA. |
| |
Abstract: | Most patients succumbing to colorectal cancer fail with liver-predominant metastases. To make a clinical impact in this disease, a systemic or whole-liver therapy may be required, whereas most cancer gene therapy approaches are limited in their ability to treat beyond local disease. As a preclinical model for cancer gene therapy, recombinant adenovirus containing the human IFN-beta (hIFN-beta) cDNA was delivered systemically in nude mouse xenograft models of human colorectal cancer liver metastases. The vector targeted hepatocytes that produced high levels of hIFN-beta in the liver, resulting in a profound apoptotic response in the tumors and significant tumor regression. hIFN-beta gene therapy not only resulted in improved survival and long-term cure in a micrometastatic model, but provided similar benefits in a clinically relevant gross disease model. A similar recombinant adenovirus containing the murine IFN-beta (mIFN-beta) cDNA also resulted in a therapeutic response and improved survival in syngeneic mouse models of colorectal cancer liver metastases. Depletion studies demonstrate a contribution of natural killer cells to this therapeutic response. The toxicity of an adenoviral vector expressing murine IFN-beta in a syngeneic model is also presented. These encouraging results warrant further investigation of the use of cancer gene therapy for targeting metastatic disease. |
| |
Keywords: | |
|
|